World Class Team
Racho Jordanov is a biotech pioneer with more than 30 years of experience building and leading manufacturing operations in development-stage and multi-national biopharmaceutical companies. Mr. Jordanov started his career with Genentech, Inc. in 1981 in San Francisco, where he led the facility start-up and managed on-going commercial manufacturing of the first biotech products to be approved by FDA: insulin and rhGH.
Over his 20-year career at Genentech Mr. Jordanov was at the forefront of innovations in biopharmaceutical manufacturing, from introducing the first processes for monoclonal antibody (mAb) production, to establishing Genentech’s outsourcing capabilities for drug substance, drug product and medical devices, to most recently starting-up new biomanufacturing facilities in the US and Singapore.
In addition to Genentech, Mr. Jordanov led North America manufacturing operations for Serono S.A. (now Merck Serono; Switzerland) and served as the Vice President of Manufacturing and Operations for two California-based biotech start-ups: Cholestech and Telios Pharmaceuticals.
Mr. Jordanov earned his B.A. in Biology from the University of California, San Diego, and an M.B.A. from National University in San Diego.
Rose is the co-founder and COO of JHL Biotech, Inc., Cayman as well as the General Manager of JHL Biotech, Taiwan. She is a true believer and supporter of JHL Biotech’s mission statement, to make affordable world- class biological therapeutics. Her experience in the industry has enabled her to gather a group of passionate biotech veterans and implement lean manufacturing processes using innovative technology, governed by top notch quality control systems.
Rose is the President and Founder of TLC Charities, Inc. which was established in December 2006 in California, USA. TLC Charities, Inc. financially supports and encourages disadvantaged children in their endeavors for education. Rose is a dreamer with passion and enthusiasm. Her goal is to combine the missions of JHL Biotech and TLC Charities to make this world a better place to live.
Rose worked at Genentech from 1987-2009 in various departments such as GMP Systems, Clinical Manufacturing, Clinical Packaging, Commercial Packaging and Biochemical Project Manager and worked at Eusol Biotech, Inc. as a plant director from 2009-2012. She holds a B.S. degree in pharmacy and is a registered pharmacist in Taiwan.
Peter Pang, Ph.D.
From 2008 to 2013, he was General Manager, Scientific Affairs and later Assistant Director, Regulatory Affairs at New B Innovation Ltd where he directed the nonclinical development and regulatory programs for human and veterinary oxygen carrying therapeutics.
Rong Chen, MD, Ph.D.
Dr. Chen joins the company from his previous role as Chief Medical Officer at Phagelux, a biologics company in Shanghai, Chief Medical Officer at CASI Pharmaceuticals, Vice President and Head of Regulatory Excellence for China/HK area at GlaxoSmithKline, Medical Director for the Asia Pacific region at Bayer Schering Pharma, and Medical Director for China at Sanofi. He also previously held several clinical and research positions in Australia.
Sohail is a certified ISO 9001:2008 and cGMP lead auditor with over 20 years cGMP quality leadership experience in biotechnology industry including development and deployment of quality systems and business processes to ensure regulatory compliance and business needs. Prior to joining JHL, Sohail has worked at Genentech (San Francisco and Singapore), Imclone/Eli Lilly, MONSANTO, and NovoNordisk/Novozymes (North America) within various quality functions including both QA and QC.
Andreas Nechansky, Ph.D.
Dr. Andreas Nechansky has more than 15 years of experience in the biotech industry and his last position was Chief Operating Officer of a GMP certified analytical service provider. His experience lies within the field of analytical characterization of Biopharmaceuticals and Biosimilars with a strong focus on Bioassays.
Zack Zheng, Ph.D.
Zack has more than 16 years of broad industrial experience from process development and scale up, to cGMP manufacturing, as well as analytical development for different molecules including monoclonal antibodies, therapeutic proteins and vaccines in US and China. He holds a B.Sc. in chemistry from Beijing Normal University, a Ph.D. from Nankai University, and was a postdoctoral fellow in chemistry and biochemistry at University of Delaware.
Allen Ho, Ph.D.
Dr. Ho has more than 17 years of biotech research experience of which with 6+ years in Regulatory Affairs.
He has strong experience in method development, transfer, and validation to support IND and BLA and is also familiar with CFDA, EMEA, US Regulation on IND filing. Before joining JHL, Dr. Ho was the Head of Research and Development at PharmaEssentia Corp.
Joseph Liu, Ph.D.
Dr. Liu has more than 14 years of pharmaceutical experience in strategic, managing and technical roles for the therapeutic biologics development from early phase to commercial phase. He has profound experience in Formulation development, Analytical method development and Technical transfer. In addition, he also has some practical experience of cGMP, CMC coordination related to biologic pipelines and Regulatory requirements from several BLA filings while he was working at Lilly.
Mahalia is an accomplished and results-oriented leader in Biologics Drug Substance Manufacturing with 18+ years serving in various leadership roles in Process Development, Manufacturing Sciences and Technology, Engineering, and Drug Substance Commercial Manufacturing. Prior to joining JHL, she was an Associate Director, Manufacturing Technical Support and later, Engineering at Genentech Oceanside Operations.
Yen has over 20 years of HR management experience with strong expertise in organizational and people development. Prior to JHL, Yen was the CHRO of Foxconn Medical Subgroup, SVP of Talent at Standard Chartered Taiwan and Northeast Asia Learning & Talent Development Manager for Abbott. Yen holds BS in Applied Mathematics from UC Berkeley.